Predicting coronary graft occlusion in males with type 2 diabetes: an annual prospective study
https://doi.org/10.25207/1608-6228-2020-27-4-189-200
Abstract
Aim. Identification of factors affecting coronary bypass graft patency in patients with type 2 diabetes (T2D) during one year after coronary bypass grafting.
Materials and methods. Coronary artery bypass grafting for stable effort angina was ordered in 23 men with T2D. The patients had transthoracic echocardiogram before surgery. All patients were verified for lupus anticoagulant (LA) in blood on the 14th day after surgery. A year later, the patients underwent coronary shuntography to assess bypass patency.
Results. LA was detected in 15 of 23 patients (65%). One year after surgery, occlusions of coronary shunts were revealed in 10 of 23 patients. In patients with coronary shunt occlusions, end-diastolic and end-systolic dimensions, end-diastolic and end-systolic volumes, end-systolic and end-diastolic indices (EDD, ESD, EDV, ESV, ESI, EDI, respectively), as well as the LA ratio significantly exceeded those in patients without occlusions (Mann—Whitney p values 0.004, 0.012, 0.012, 0.006, 0.006, 0.004, 0.017, respectively). A method is proposed for predicting coronary shunt occlusions based on assessment of end-diastolic volume of left ventricle and the LA ratio.
Conclusion. Echocardiographic values for left ventricle (EDD, ESD, EDV, ESV, ESI, EDI) and the LA ratio are predictors of coronary graft occlusions in patients with type 2 diabetes.
About the Authors
N. S. Lisytenko
Omsk State Medical University
Russian Federation
Russian Federation
Natalia S. Lisytenko — Postgraduate Student, Chair of Hospital Therapy and Endocrinology
Lenina str., 12, Omsk, 644099
tel.: +7 (904) 825-82-57
N. A. Morova
Omsk State Medical University
Russian Federation
Russian Federation
Nataliya A. Morova — Dr. Sci. (Med.), Prof., Chair of Hospital Therapy and Endocrinology
Lenina str., 12, Omsk, 644099
V. N. Tsekhanovich
Omsk State Medical University; Regional Clinical Hospital
Russian Federation
Russian Federation
Valeriy N. Tsekhanovich — Dr. Sci. (Med.), Prof., Chair of Faculty Surgery and Urology, Omsk State Medical University; Head of the Cardiac Surgery Unit, Regional Clinical Hospital
Lenina str., 12, Omsk, 644099
Berezovaya str., 3, Omsk, 644111
References
1. Gaudino M., Antoniades C., Benedetto U., Deb S., Di Franco A., Di Giammarco G., et al.; ATLANTIC (Arterial Grafting International Consortium) Alliance. Mechanisms, Consequences, and Prevention of Coronary Graft Failure. Circulation. 2017; 136(18): 1749–1764. DOI: 10.1161/CIRCULATIONAHA.117.027597
2. Yahagi K., Kolodgie F.D., Otsuka F., Finn A.V., Davis H.R., Joner M., Virmani R. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat. Rev. Cardiol. 2016; 13(2): 79–98. DOI: 10.1038/nrcardio.2015.164
3. Raza S., Blackstone E.H., Houghtaling P.L., Rajeswaran J., Riaz H., Bakaeen F.G., et al. 3rd. Influence of Diabetes on Long-Term Coronary Artery Bypass Graft Patency. J. Am. Coll. Cardiol. 2017; 70(5): 515–524. DOI: 10.1016/j.jacc.2017.05.061
4. Kuznetsova A.V., Teplyakov A.T., Protopopova N.V. Assessment of the effect of carbohydrate metabolism disturbance on the course of coronary heart disease in patients with diabetes mellitus undergoing coronary revascularization. Kompleksnye Problemy Serdechno-Sosudistykh Zabolevanii. 2014; 3: 59 (In Russ.).
5. Ogawa S., Okawa Y., Sawada K., Motoji Y., Goto Y., Kimura A., et al. Impact of glucose control on early vein graft failure after coronary artery bypass grafting: one-month angiographic results. Interact. Cardiovasc. Thorac. Surg. 2017; 24(2): 216–221. DOI: 10.1093/icvts/ivw343
6. Dinckal M.H., Ozkaynak B., Mert B., Sahin I., Sigirci S., Gulsen K., et al. The relationship between antibeta 2 glycoprotein antibodies and SYNTAX score in patients undergoing coronary artery by-pass graft surgery. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(17): 2556–2561.
7. Celińska-Lowenhoff M., Iwaniec T., Padjas A., Musiał J., Undas A. Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation. Thromb. Haemost. 2014; 112(2): 287–296. DOI: 10.1160/TH13-11-0980
8. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb. Res. 2004; 114(5–6): 593–595. DOI: 10.1016/j.thromres.2004.07.012
9. Milgrom A., Lee K., Rothschild M., Makadia F., Duhon G., Min S., et al. Thrombophilia in 153 Patients With Premature Cardiovascular Disease ≤Age 45. Clin. Appl. Thromb. Hemost. 2018; 24(2): 295–302. DOI: 10.1177/1076029617703481
10. Hoxha A., Banzato A., Ruffatti A., Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun. Rev. 2017; 16(2): 173–178. DOI: 10.1016/j.autrev.2016.12.010
11. Wiemers P.D., Marney L., White N., Bough G., Hustig A., Tan W., et al. Comorbidities and Ventricular Dysfunction Drive Excess Mid-Term Morbidity in an Indigenous Australian Coronary Revascularisation Cohort. Heart. Lung. Circ. 2019; 28(6): 874–883. DOI: 10.1016/j.hlc.2018.04.285
12. Ji Q., Xia L.M., Shi Y.Q., Ma R.H., Shen J.Q., Ding W.J., Wang C.S. Impact of severe left ventricular dysfunction on in-hospital and mid-term outcomes of Chinese patients undergoing first isolated off-pump coronary artery bypass grafting. J. Cardiothorac. Surg. 2017; 12(1): 87. DOI: 10.1186/s13019-017-0651-z
13. Prior D.L., Stevens S.R., Holly T.A., Krejca M., Paraforos A., Pohost G.M., et al.; STICH Trial Investigators. Regional left ventricular function does not predict survival in ischaemic cardiomyopathy after cardiac surgery. Heart. 2017; 103(17): 1359–1367. DOI: 10.1136/heartjnl-2016-310693
14. Hessian R., Jabagi H., Ngu J.M.C., Rubens F.D. Coronary Surgery in Women and the Challenges We Face. Can. J. Cardiol. 2018; 34(4): 413–421. DOI: 10.1016/j.cjca.2018.01.087
15. Gavrilova N.E., Metelskaya V.A., Perova N.V., Yarovaya E.B., Boytsov S.A., Mazaev V.P. Factor analysis and individual prognosis for the patients with first revealed arterial hypertension. Russian Journal of Cardiology. 2014; (6): 24–29 (In Russ., English abstract). DOI: 10.15829/1560-4071-2014-6-24-29
16. Esper R.B., Farkouh M.E., Ribeiro E.E., Hueb W., Domanski M., Hamza T.H., et al. SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial. J. Am. Coll. Cardiol. 2018; 72(23PtA): 2826–2837. DOI: 10.1016/j.jacc.2018.09.046
17. Bockeria L.A., Sokolskaya N.O., Kopylova N.S., Alshibaya M.M. Chocardiographic predictors of the severity of the early postoperative period in patients after surgical myocardial revascularization. Anesteziologiya i Reanimatologiya. 2015; 60 (5); 8–11 (In Russ., English abstract).
18. Kręcki R., Arazińska A., Peruga J.Z., Plewka M., Kasprzak J.D., Krzemińska-Pakuła M. Characteristics, management and five-year outcomes of patients with high risk, stable multivessel coronary heart disease. Kardiol. Pol. 2014; 72(3): 262–268. DOI: 10.5603/KP.a2013.0285
Review
For citations:
Lisytenko N.S., Morova N.A., Tsekhanovich V.N. Predicting coronary graft occlusion in males with type 2 diabetes: an annual prospective study. Kuban Scientific Medical Bulletin. 2020;27(4):189-200. (In Russ.) https://doi.org/10.25207/1608-6228-2020-27-4-189-200
Views:
345
Email this article 